A. A. Filipchenko, “Caspases: regulators of apoptosis and other cellular functions,” Biokhimiya, 68, No. 4, 453–466 (2003).
N. Bahcekapili. G. Uzüm, C. Gökkusu, et al., “The relationship between erythropoietin pre-treatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats,” Life Sci, 80, No. 14, 1245–1251 (2007).
J. E. Baker, “Erythropoietin mimics ischemic preconditioning,” Vascul. Pharmacol., 42, No. 5–6, 233–241 (2005).
W. A. Banks, N. L. Jumbe, C. L. Farrell, et al., “Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and m urine erythropoietin and the analog darbepoetin alfa,” Eur. J. Pharmacol., 505, No. 1–3, 93–101 (2004).
B. B. Beleslin-Cokic, V. P. Cokic, X. Yu, et al., “Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells,” Blood, 104, No. 7, 2073–2080 (2004).
A. Benraiss, E. Chmielnicki, K. Lerner, et al., “Adenoviral brainderived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult fore-brain,” J. Neurosci., 21, No. 17, 6718–6731 (2001).
M. Bernaudin, H. H. Marti, S. Roussel, et al., “A potential role for erythropoietin in focal permanent cerebral ischemia in mice,” J. Cereb. Blood Flow Metab., 19, No. 6, 643–651 (1999).
M. Bernaudin, A. Bellail, H. H. Marti, et al., “Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain,” Glia, 30, No. 3, 271–278 (2000).
M. Bernaudin, A. S. Nedelec, D. Divoux, et al., “Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain,” J. Cereb. Blood Flow Metab., 22, No. 4, 393–403 (2002).
M. L. Brines, P. Ghezzi, S. Keenan, et al., “Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury,” Proc. Natl. Acad. Sci. USA, 97,No. 19, 10526–10531 (2000).
M. Brines, G. Grasso, F. Fiordaliso, et al., “Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor,” Proc. Natl. Acad. Sci. USA, 101, No. 41, 14907–14912 (2004).
M. Brines and A. Cerami, “Discovering erythropoietin’s extrahematopoietic functions: biology and clinical promise,” Kidney Int., 70, No. 2, 246–250 (2006).
V. Calabrese, G. Scapagnini, A. Ravagna, et al., “Molecular chaperones and their roles in neural cell differentiation,” Dev. Neurosci., 24, No. 1, 1–13 (2002).
G. Calapai, M. C. Marciano, F. Corica, et al., “Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation,” Eur. J. Pharmacol., 401, No. 3, 349–356 (2000).
P. Carnot and C. Deflandre, “Sur l’activité hematopoietique de serum au cours de la regeneration du sang,” C. R. Acad. Sci., 143, 384–286 (1906).
M. A. Catania M. C. Marciano, A. Parisi, et al., “Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils,” Eur. J. Pharmacol., 437, No. 3, 147–150 (2002).
M. Celik, N. Gökmen, S. Erbayraktar, et al., “Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury,” Proc. Natl. Acad. Sci. USA, 99, No. 4, 2258–2263 (2007).
O. Z. Chi, C. Hunter, X. Liu, and H. R. Weiss, “Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia,” Exp. Neurol., 204, No. 1, 283–287 (2007).
O. Z. Chi, C. Hunter, X. Liu, and H. R. Weiss, “Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia,” Pharmacology, 82, No. 1, 38–42 (2008).
D. W. Choi and S. M. Rothman, “The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death,” Ann. Rev. Neurosci., 13, 171–182 (1990).
Z. Z. Chong, J. A. Kang, and K. Maiese, “Erythropoietin is a novel vascular protectant through activation of Aktl and mitochondrial modulation of cysteine proteases,” Circulation, 106, No. 23, 2973–2979 (2002).
M. Crompton, “Mitochondrial intermembrane junctional complexes and their role in cell death,” J. Physiol., 529, 11–21 (2000).
S. R. Datta, A. Brunet, and M. E. Greenberg, “Cellular survival: a play in three Akts,” Genes Dev., 13, No. 22, 2905–2927 (1999).
M. Digicaylioglu, S. Bichet, H. H. Marti, et al., “Localization of specific erythropoietin binding sites in defined areas of the mouse brain,” Proc. Natl. Acad. Sci. USA, 92, No. 9, 3717–3720 (1995).
M. Digicaylioglu and S. A. Lipton, “Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-KB signalling cascades,” Nature, 412, No. 6847, 641–647 (2001).
S. A. Doggrell, “A neuroprotective derivative of erythropoietin that is not erythropoietic,” Exp. Opin. Investig. Drugs, 13, No. 11, 1517–1519 (2004).
H. Ehrenreich, N. Hasselblatt, C. Dembowski, et al., “Erythropoietin therapy for acute stroke is both safe and beneficial,” Mol. Med., 8, No. 8, 495–505 (2002).
S. Erbayraktar, G. Grasso, A. Sfacteria, et al., “Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo,” Proc. Natl. Acad. Sci. USA, 100, No. 11, 6741–6746 (2003).
Y. F. Fan, C. Z. Lu, J. Xie, et al., “Apoptosis inhibition in ischemic brain by intraperitoneal PTD-BIR3-RING (XIAP),” Neurochem. Int., 48, No. 1, 50–59 (2006).
F. F. Gonzalez, P. McQuillen, D. Mu, et al., “Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke,” Dev. Neurosci., 29, No. 4–5, 321–330 (2007).
P. M. Grimley, F. Dong, and H. Rui, “Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation,” Cytokine Growth Factor Rev., 10, No. 2, 131–157 (1999).
D. J. Hausenloy and D. M. Yellon, “Survival kinases in ischemic preconditioning and postconditioning,” Cardiovasc. Res., 70, No. 2, 240–253 (2006).
Y. Higuchi, H. Hattori, T. Kume, et al., “Increase in nitric oxide in the hypoxic-ischemic neonatal rat brain and suppression by 7-nitroindazole and aminomianidine,” Eur. J. Pharmacol., 342, No. 1, 47–49 (1998).
K. Imaizumi, T. Morihara,Y. Mori, et al., “The cell death-promoting gene DPS, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid β-protein,” J. Biol. Chem., 274, No. 12, 7975–7981 (1999).
L. P. Kane,V. S. Shaipor, D. Stokoe, and A. Weiss, “Induction of NF-κB by the Akt/PKB kinase,” Curr. Biol., 9, No. 11, 601–604 (1999).
M. Kawakami, M. Sekiguchi, S. Sato, et al., “Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia,” J. Biol. Chem., 276, No. 42, 39469–39475 (2001).
E. Kilic, U. Kilic, J. Zoliz, et al., “Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways,” FASEB J., 19, No. 14, 2026–2028 (2005).
A. Kumral, E. Ozer, O. Yilmaz, et al., “Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats,” Biol. Neonate, 83, No. 3, 224–228 (2003).
A. Kumral, H. Baskin, N. Gokmen, et al., “Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin?” Biol. Neonate, 85, No. 1, 51–54 (2004).
A. Kumral, S. Gonenc, O. Ackigoz, et al., “Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats,” Biol. Neonate, 87, No. 1, 15–18 (2005).
A. Kumral, S. Genc, E. Ozer, et al., “Erythropoietin downregulates Bax and DP5 proapoptotic gene expression in neonatal hypoxicischemic brain injury,” Biol. Neonate, 89, No. 3, 205–210 (2006).
J. V. Lafuente, E. G. Argandoña, and B. Mitre, “VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers,” J. Neural Transm., 113, No. 4, 487–496 (2006).
P. A. Lapchak, A. Kirkeby, J. A. Zivin, and T. N. Sager, “Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits,” Brain Res., 1238, 208–214 (2008).
P. Lewczuk, M. Hasselblatt, H. Kamrowski-Kruch, et al., “Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin,” Neuroreport, 11, No. 16, 3485–3488 (2000).
F. Li, Z. Z. Chong, and K. Maiese, “Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways,” Neurosignals, 13, No. 6, 265–289 (2004).
L. Li, Q. Jiang, G. Ding, et al., “MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemia,” Stroke, 40, No. 3, 936–941 (2009).
Y. Li, Z. Lu, C. L. Keogh, et al., “Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice,” J. Cereb. Blood Flow Metab., 27, No. 5, 1043–1054 (2007a).
Y. Li, Z. Y. Lu, M. Ogle, and L. Wei, “Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice,” Neurochem. Res., 32, No. 12, 2132–2141 (2007b).
R. Liu, A. Suzuki, Z. Guo, et al., “Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro,” J. Neurochem., 96, No. 4, 1101–1110 (2006).
S. Malhotra, S. I. Savitz, L. Ocava, and D. M. Rosenbaum, “Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack,” J. Neurosci. Res., 83, No. 1, 19–27 (2006).
B. P. Meloni, P. A. Tilbrook, S. Boulos, et al., “Erythropoietin preconditioning in neuronal cultures: signaling, protection from in vitro ischemia, and proteomic analysis,” J. Neurosci. Res., 83, No. 4, 584–593 (2006).
M. Motero, F. R. Poulsen, J. Noraberg, et al., “Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures,” Exp. Neurol., 204, No. 1, 106–117 (2007).
E. Morishita, S. Masuda, M. Nagao, et al., “Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death,” Neurosci., 76, No. 1, 105–116 (1997).
A. Nagai, E. Nakagawa, H. B. Choi, et al., “Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture,” J. Neuropathol. Exp. Neurol., 60, No. 4, 386–392 (2001).
C. T. Noguchi, P. Asavaritikrai, R. Teng, and Y. Jia, “Role of erythropoietin in the brain,” Crit. Rev. Oncol. Hematol., 24, No. 2, 159–171 (2007).
S. K. Peirce and H. W. Findley, “The MDM 2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73,” int. J. Oncol., 34, No. 5, 1395–1402 (2009).
K. Prass, A. Scharff, K. Ruscher, et al., “Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin,” Stroke, 34, No. 8, 1981–1986 (2003).
P. Romsi, E. Rönkä, K. Kiviluoma, et al., “Potential neuroprotective benefits of erythropoietin during experimental hypothermic circulatory arrest,” J. Thorac. Cardiovasc. Surg., 124, No. 4, 714–723 (2002).
K. Ruscher, D. Freyer, M. Karsch, et al., “Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model,” J. Neurosci., 22, No. 23, 10291–10301 (2002).
Y. Sadamoto, K. Igase, M. Sakanaka, et al., “Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery,” Biochem. Biophys. Res. Commun., 253, No. 1, 26–32 (1998).
M. Sakanaka, T. C. Wen, S. Matsuda, et al., “In vivo evidence that erythropoietin protects neurons from ischemic damage,” Proc. Natl. Acad. Sci. USA, 95, No. 8, 4635–4640 (1998).
A. D. Sinor and D. A. Greenberg, “Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity,” Neurosci. Lett., 290, No. 3, 213–215 (2000).
A. L. Sirén, M. Fratelli, M. Brines, et al., “Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress,” Proc. Natl. Acad. Sci. USA, 98, No. 7, 4044–4049 (2001).
A. Sola, M. Rogido, B. H. Lee, et al., “Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats,” Pediatr. Res., 57, No. 4, 481–487 (2005).
E. Spandou, S. Papaoutsopoulou, V. Soubasi, et al., “Hypoxiaischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain,” Brain Res., 1021, No. 2, 167–172 (2004).
Y. Sun, C. Zhou, P. Polk, et al., “Mechanisms of erythropoietininduced brain protection in neonatal hypoxia-ischemia rat model,” J. Cereb. Blood Flow Metab., 24, No. 2, 259–270 (2004).
Y. Sun, J. W. Calvert, and J. H. Zhang, “Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration,” Stroke, 36, No. 8, 1672–1678 (2005).
R. Takahashi, Q. Deveraux, I. Tamm, et al., “A single BIR domain of XIAP sufficient for inhibiting caspases,” J. Biol. Chem., 273, No. 14, 7787–7790 (1998).
P. J. Thornalley and M. Vasák, “Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals,” Biochem. Biophys Acta, 827, No. 1, 36–44 (1985).
M. Tsuji, Y. Higuchi, K. Shiraishi, et al., “Protective effect of aminoguanidine on hypoxic-ischemic brain damage and temporal profile of brain nitric oxide in neonatal rat,” Pediatr. Res., 47, No. 1, 79–83 (2000).
G. Valen, Z. Q. Yan, and G. K. Hansson, “Nuclear factor kappa-B and the heart,” J. Am. Coll. Cardiol., 38, No. 2, 307–314 (2001).
A. van der Kooij, F. Groenendaal, A. Kavelaars, et al., “Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia,” Brain Res. Rev., 59, No. 1, 22–33 (2008).
P. Villa, P. Bigini, T. Mennini, et al., “Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis,” J. Exp. Med., 198, No. 6, 971–975 (2003).
P. Villa, J. van Beek, A. K. Larsen, et al., “Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives,” J. Cereb. Blood Flow Metab., 27, No. 3, 552–563 (2007).
K. Wakida, M. Shimazawa, I. Hozumi, et al., “Neuroprotective effect of erythropoietin, and role of metallothionein-1 and −2, in permanent focal cerebral ischemia,” Neurosci., 148, No. 1, 105–114 (2007).
L. Wang, Z. Zhang, Y. Wang, et al., “Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats,” Stroke, 35, No. 7, 1732–1737 (2004).
L. Wang, Z. G. Zhang, R. L. Zhang, et al., “Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration,” J. Neurosci., 26, No. 22, 5996–6003 (2006).
X. Wang, C. Zhu, X. Wang, et al., “The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin,” J. Neurochem., 91, No. 4, 900–910 (2004).
Y. Wang, Z. G. Zhang, K. Rhodes, et al., “Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia,” Brit. J. Pharmacol., 151, No. 8, 1377–1384 (2007).
L. Wei, B. H. Han, Y. Li, et al., “Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats,” J. Pharmacol. Exp. Ther., 317, No. 1, 109–116 (2006).
T. C. Wen, Y. Sadamoto, J. Tanaka, et al., “Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression,” J. Neurosci. Res., 67, No. 6, 795–803 (2002).
C. Wiessner, P. R. Allegrini, D. Ekatodramis, et al., “Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin,” J. Cereb. Blood Flow Metab., 21, No. 7, 857–864 (2001).
D. Xu, Y. Bureau, D. C. McIntyre, et al., “Attenuation of ischemiainduced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus,” J. Neurosci., 19, No. 12, 5026–5033 (1999).
R. Yamaji, T. Okada, M. Moriya, et al., “Brain capillary endothelial cells express two forms of erythropoietin receptor mRNAi,” Eur. J. Biochem., 239, No. 2, 494–500 (1996).
F. Zhang,A. P. Signore, Z. Zhou, et al., “Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms,” J. Neurosci. Res., 83, No. 7, 1241–1251 (2006).
F. Zhang, S. Wang, G. Cao, et al., “Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia,” Neurobiol. Dis., 25, No. 1, 45–53 (2007).